NPS Pharmaceuticals to Host Conference Call to Discuss FDA Approval of Gattex® (teduglutide [rDNA Origin]) for Injection for...
03 January 2013 - 12:00AM
Business Wire
NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will host a conference
call to discuss its commercialization plan for Gattex, including
the cost of therapy, today at 5:00 p.m. Eastern Time. To
participate in the conference call, dial (800) 706-7748 and use
pass code 18085144. International callers may dial (617) 614-3473,
using the same pass code. In addition, a live audio of the
conference call will be available over the Internet. Interested
parties can access the event through the investors’ calendar of
events page on the NPS website at http://www.npsp.com/calendar.
For those unable to participate in the live call, a replay will
be available at (888) 286-8010, with pass code 79197503, until
midnight Eastern Time, January 16, 2013. International callers may
access the replay by dialing (617) 801-6888, using the same pass
code. The webcast will also be available through the NPS website
for the same period.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on
bringing orphan products to patients with rare disorders and few,
if any, therapeutic options. The company’s lead product,
Gattex® 0.05 mg/kg/d (Teduglutide [rDNA origin]) for
Injection, for subcutaneous use is FDA-approved for the treatment
of adult patients with short bowel syndrome (SBS) who are dependent
on parenteral support. NPS is also developing Natpara®
(rhPTH[1-84]) for the treatment of adult hypoparathyroidism and
expects to submit its Biologic License Application (BLA) to the FDA
in mid-2013. NPS's earlier stage pipeline includes two calcilytic
compounds, NPSP790 and NPSP795, with potential application in rare
disorders involving increased calcium receptor activity, such as
autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS
complements its proprietary programs with a royalty-based portfolio
of products and product candidates that includes agreements with
Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin,
and Takeda GmbH.
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More NPS Pharmaceuticals, Inc. News Articles